Clinical Trials Directory

Trials / Conditions / Covid19 Vaccine

Covid19 Vaccine

14 registered clinical trials studyying Covid19 Vaccine — 1 currently recruiting.

StatusTrialSponsorPhase
CompletedA Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults
NCT05011526
Medigen Vaccine Biologics Corp.Phase 3
CompletedA Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults
NCT05079633
National Taiwan University HospitalPhase 4
WithdrawnIntraDermal Versus Intramuscular Comirnaty® Efficacy Study
NCT05029245
Department of Medical Services Ministry of Public Health of ThailandPhase 3
CompletedPTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Stud
NCT05175742
Providence Therapeutics Holdings Inc.Phase 2
CompletedA Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study
NCT05038618
Medigen Vaccine Biologics Corp.Phase 2
CompletedA Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents
NCT04951388
Medigen Vaccine Biologics Corp.Phase 2
CompletedA Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Stud
NCT05048849
Medigen Vaccine Biologics Corp.Phase 2
UnknownInvestigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protei
NCT04730895
Kafrelsheikh UniversityPhase 1 / Phase 2
CompletedA Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults
NCT04822025
Medigen Vaccine Biologics Corp.Phase 2
RecruitingCOVID-19 Vaccines Safety Tracking (CoVaST)
NCT04834869
Masaryk University—
CompletedImmunogenicity of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease
NCT04818892
University of Wisconsin, Madison—
CompletedCovid-19 Vaccine Response in Elderly Subjects
NCT04760704
University Hospital, Lille—
CompletedPTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This S
NCT04765436
Providence Therapeutics Holdings Inc.Phase 1
CompletedA Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult
NCT04695652
Medigen Vaccine Biologics Corp.Phase 2